On October 30, Illumina fell 12.59% in Regular Trading, trading at $250.43, with turnover of $49.16 million.
The move followed the company’s latest quarterly report, where adjusted EPS of $1.62 beat the $1.36 consensus estimate and full-year adjusted operating margin guidance was raised to 23.6%, but quarterly revenue of $1.129 billion missed expectations of about $1.154 billion.
Public updates also showed China revenue declined 0.1% in the quarter, a key factor investors focused on despite stronger free cash flow of $378 million and maintained organic revenue growth guidance of more than 4%. A later analyst update raised a price target to $250 from $215, but that did not offset the market’s concern over top-line softness and regional pressure.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments